UBS Group’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-143,080
| Closed | -$1.92M | – | 10117 |
|
|
2023
Q1 | $1.92M | Hold |
143,080
| – | – | ﹤0.01% | 3479 |
|
|
2022
Q4 | $1.77M | Hold |
143,080
| – | – | ﹤0.01% | 3516 |
|
|
2022
Q3 | $2M | Hold |
143,080
| – | – | ﹤0.01% | 3168 |
|
|
2022
Q2 | $1.98M | Hold |
143,080
| – | – | ﹤0.01% | 3161 |
|
|
2022
Q1 | $2.33M | Hold |
143,080
| – | – | ﹤0.01% | 3291 |
|
|
2021
Q4 | $2.33M | Hold |
143,080
| – | – | ﹤0.01% | 3593 |
|
|
2021
Q3 | $2.13M | Sell |
143,080
-436,040
| -75% | -$6.98M | ﹤0.01% | 3517 |
|
|
2021
Q2 | $11.6M | Hold |
579,120
| – | – | ﹤0.01% | 1910 |
|
|
2021
Q1 | $13.4M | Hold |
579,120
| – | – | ﹤0.01% | 1717 |
|
|
2020
Q4 | $14.3M | Hold |
579,120
| – | – | ﹤0.01% | 1579 |
|
|
2020
Q3 | $24M | Hold |
579,120
| – | – | 0.01% | 1050 |
|
|
2020
Q2 | $27.7M | Hold |
579,120
| – | – | 0.01% | 894 |
|
|
2020
Q1 | $36.5M | Hold |
579,120
| – | – | 0.02% | 687 |
|
|
2019
Q4 | $71.8M | Hold |
579,120
| – | – | 0.03% | 582 |
|
|
2019
Q3 | $38.4M | Hold |
579,120
| – | – | 0.01% | 831 |
|
|
2019
Q2 | $46.1M | Hold |
579,120
| – | – | 0.02% | 708 |
|
|
2019
Q1 | $64.8M | Hold |
579,120
| – | – | 0.03% | 517 |
|
|
2018
Q4 | $58.4M | Hold |
579,120
| – | – | 0.03% | 531 |
|
|
2018
Q3 | $73.2M | Hold |
579,120
| – | – | 0.03% | 516 |
|
|
2018
Q2 | $48.6M | Hold |
579,120
| – | – | 0.02% | 669 |
|
|
2018
Q1 | $35.6M | Hold |
579,120
| – | – | 0.02% | 810 |
|
|
2017
Q4 | $33.8M | Hold |
579,120
| – | – | 0.01% | 863 |
|
|
2017
Q3 | $33.6M | Hold |
579,120
| – | – | 0.02% | 815 |
|
|
2017
Q2 | $70.1M | Hold |
579,120
| – | – | 0.04% | 449 |
|
|
2017
Q1 | $65.5M | Hold |
579,120
| – | – | 0.04% | 456 |
|
|
2016
Q4 | $62.9M | Hold |
579,120
| – | – | 0.03% | 448 |
|
|
2016
Q3 | $95.3M | Buy |
579,120
+75,540
| +15% | +$11.9M | 0.06% | 331 |
|
|
2016
Q2 | $71.9M | Buy |
+503,580
| New | +$73.4M | 0.05% | 390 |
|
|
2016
Q1 | – | Sell |
-700
| Closed | -$105K | – | 8337 |
|
|
2015
Q4 | $105K | Hold |
700
| – | – | ﹤0.01% | 5164 |
|
|
2015
Q3 | $116K | Hold |
700
| – | – | ﹤0.01% | 5104 |
|
|
2015
Q2 | $169K | Hold |
700
| – | – | ﹤0.01% | 5015 |
|
|
2015
Q1 | $197K | Sell |
700
-4,400
| -86% | -$953K | ﹤0.01% | 4897 |
|
|
2014
Q4 | $796K | Buy |
+5,100
| New | +$942K | ﹤0.01% | 3754 |
|
UBS Group's ICPT Position: Q4 2023 in Review
UBS Group sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 2,999,188 shares — an estimated $55.6M sold.
UBS Group first reported a position in ICPT in Q4 2014 and held it in 36 quarters. The position peaked at $55.6M in Q3 2023. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- UBS Group reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- UBS Group sold 2,999,188 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $55.6M.
- UBS Group first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2014 and held it in 36 quarters.
- UBS Group's Intercept Pharmaceuticals, Inc. position peaked at $55.6M in Q3 2023.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on UBS Group's 13F filing for Q4 2023, filed 9 Feb 2024.